The treatment of vascular endothelial growth factor (VEGF) blocking agent bevacizumab potentially remodels the pathologic and disorganized tumor vessels [8] and in part accounts for the synergistic effect of the combination. The gene discussed is VEGFA; the disease is neoplasm.